Tarsus Pharmaceuticals (TARS) EBITDA Margin (2021 - 2026)
Tarsus Pharmaceuticals (TARS) recorded quarterly EBITDA Margin of 4.72% in Q1 2026, up 13.59% quarter-over-quarter from 5.46% in Q4 2025, and up 2747.0% on a YoY basis from 0.17% in Q1 2025.
Tarsus Pharmaceuticals (TARS) EBITDA Margin (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' EBITDA Margin history runs 6 years deep, the most recent figure standing at 4.72% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 2747.0% year-over-year to 4.72%; the TTM figure through Mar 2026 stood at 9.09% (up 3575.0% YoY), while the FY2025 annual figure was 14.67%, up 4839.0% from the prior year.
- EBITDA Margin was 4.72% for Q1 2026 at Tarsus Pharmaceuticals, up from 5.46% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 4.72% in Q1 2026 to a low of 3754.73% in Q1 2022.
- Historically, EBITDA Margin has averaged 509.62% across 5 years, with a median of 47.59% in 2024.
- Biggest YoY gain for EBITDA Margin was 425716 bps in 2022; the steepest drop was 378577 bps in 2022.
- A 5-year view of EBITDA Margin shows it stood at 136.63% in 2022, then plunged by 135 bps to 320.4% in 2023, then surged by 89 bps to 35.06% in 2024, then surged by 84 bps to 5.46% in 2025, then grew by 14 bps to 4.72% in 2026.
- The last three EBITDA Margin figures came in at 4.72% (Q1 2026), 5.46% (Q4 2025), and 10.39% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn | -4.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72% |
| Dec 31, 2025 | -5.46% |
| Sep 30, 2025 | -10.39% |
| Jun 30, 2025 | -19.86% |
| Mar 31, 2025 | -32.19% |
| Dec 31, 2024 | -35.06% |
| Sep 30, 2024 | -47.59% |
| Jun 30, 2024 | -81.84% |
| Mar 31, 2024 | -129.62% |
| Dec 31, 2023 | -320.40% |
| Sep 30, 2023 | -2,091.56% |
| Mar 31, 2023 | -936.60% |
| Dec 31, 2022 | -136.63% |
| Jun 30, 2022 | -37.59% |
| Mar 31, 2022 | -3,754.73% |
| Dec 31, 2021 | -4,393.79% |
| Sep 30, 2021 | -1,265.89% |
| Jun 30, 2021 | 28.82% |
| Mar 31, 2021 | 31.04% |